Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Fujian Shengdi Pharmaceutical

Aliases
Fujian Shengdi Pharmaceutical Co., Ltd.

22 clinical trials

2 abstracts

Clinical trial
A Multi-centre, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of HRS9531injection in Healthy Subjects and Subjects With Impaired Renal Function
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Relative Bioavailability Study of Single-dose, Randomized, Open-label, Single-period, Parallel Design of HRS9531 Injection Using Different Manufacturing Processes in Healthy Subjects
Status: Completed, Estimated PCD: 2023-09-04
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered HRS9531
Status: Completed, Estimated PCD: 2022-08-24
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2023-03-29
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy
Status: Completed, Estimated PCD: 2023-06-19
Clinical trial
Efficacy and Safety of Remimazolam Tosilate for Injection for Sedation in the Intensive Care Unit (ICU) - a Multicenter, Randomized, Single Blind, Dose Finding Phase II Clinical Trial
Status: Completed, Estimated PCD: 2023-04-02
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Status: Active (not recruiting), Estimated PCD: 2024-10-08
Clinical trial
Dose Escalation Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 After Intravenous Infusion Administration in Healthy Adults
Status: Completed, Estimated PCD: 2023-06-02
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
Randomized, Double-blind, Placebo-controlled, Single-dose Ascending Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7450 in Healthy Subjects.
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Multi-center, Randomized, Single-blind, Parallel Controlled With Active Drug, Confirmatory Study to Evaluate the Efficacy and Safety of HR19006 Injection for Postoperative Parenteral Nutrition
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Phase I Clinical Study of Safety and Pharmacokinetics of Single-dose HR20013 for Injection Combined With Dexamethasone in Patients With Malignant Solid Tumors Receiving Cisplatin-based Chemotherapy
Status: Completed, Estimated PCD: 2023-01-13
Clinical trial
Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Abstract
Single-cell landscape of the immune microenvironment of leptomeningeal metastases in non-small cell lung cancer treated with pemetrexed sheath injection.
Org: Fujian Cancer Hospital, Fuzhou University, Fujian Shengdi Pharmaceutical, China National Biotec Group,
Abstract
Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib.
Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou University,
Clinical trial
Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Single Dose Incremental Phase Ib Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Randomized, Open, Parallel-designed Phase II Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
Status: Not yet recruiting, Estimated PCD: 2026-05-15
Clinical trial
A Evaluate HRS5580 for Injection for Prevention of Postoperative Nausea and Vomiting Efficacy and Safety of Ⅱ Period, Randomized, Multicenter, Dose of Exploration, Positive Control, Placebo-controlled, Double-blind, Double Simulation Trials
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
An Open Label, Tolvaptan-controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Ascending Dose of HRS-9057 in Heart Failure With Volume Overload
Status: Not yet recruiting, Estimated PCD: 2024-09-20